GlassScriptPhysician profile
Michelle L Plaster
NPI 1073762720
$8,718.01
in general payments reported to CMS, 2019-2025
57 companies · $959 in 2025
The $959 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $1,368 · 2021: $1,352 · 2022: $1,025 · 2023: $1,591 · 2024: $1,188 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,662 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.64 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,376.17 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $829.14 | 2019-2025 | |
| Amgen INC. | $630.22 | 2019-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $567.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $545.75 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Pfizer INC. | $392.51 | 2019-2025 | |
| Abbott Laboratories | $360.73 | 2020-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $309.92 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $283.76 | 2019-2021 | |
| Astellas Pharma US INC | $225.59 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $215.81 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $208.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.88 | 2019-2024 | Trintellix |
| Corcept Therapeutics | $184.00 | 2022-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.73 | 2023-2024 | Xifaxan |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Plaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.